---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006998"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:41.800394+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib

## Summary
- Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.
- CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.
- CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.
- Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.
- Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-006998
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/0001193125-26-006998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006998
- JSON: https://secwatch.observer/filing/0001193125-26-006998.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.